400 related articles for article (PubMed ID: 17825701)
1. Cost-effectiveness of a lidocaine 5% medicated plaster relative to gabapentin for postherpetic neuralgia in the United Kingdom.
Dakin H; Nuijten M; Liedgens H; Nautrup BP
Clin Ther; 2007 Jul; 29(7):1491-507. PubMed ID: 17825701
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness analysis of a lidocaine 5% medicated plaster compared with gabapentin and pregabalin for treating postherpetic neuralgia: a german perspective.
Liedgens H; Hertel N; Gabriel A; Nuijten M; Dakin H; Mitchell S; Nautrup BP
Clin Drug Investig; 2008; 28(9):583-601. PubMed ID: 18666805
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of a lidocaine 5% medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in the UK: a Markov model analysis.
Ritchie M; Liedgens H; Nuijten M
Clin Drug Investig; 2010; 30(2):71-87. PubMed ID: 20067326
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of a new 8% capsaicin patch compared to existing therapies for postherpetic neuralgia.
Armstrong EP; Malone DC; McCarberg B; Panarites CJ; Pham SV
Curr Med Res Opin; 2011 May; 27(5):939-50. PubMed ID: 21375358
[TBL] [Abstract][Full Text] [Related]
5. A cost-effectiveness comparison of desipramine, gabapentin, and pregabalin for treating postherpetic neuralgia.
O'Connor AB; Noyes K; Holloway RG
J Am Geriatr Soc; 2007 Aug; 55(8):1176-84. PubMed ID: 17661955
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of pregabalin for the management of neuropathic pain associated with diabetic peripheral neuropathy and postherpetic neuralgia: a Canadian perspective.
Tarride JE; Gordon A; Vera-Llonch M; Dukes E; Rousseau C
Clin Ther; 2006 Nov; 28(11):1922-34. PubMed ID: 17213013
[TBL] [Abstract][Full Text] [Related]
7. Comparing healthcare costs of Medicaid patients with postherpetic neuralgia (PHN) treated with lidocaine patch 5% versus gabapentin or pregabalin.
Kirson NY; Ivanova JI; Birnbaum HG; Wei R; Kantor E; Puenpatom RA; Ben-Joseph RH; Summers KH
J Med Econ; 2010; 13(3):482-91. PubMed ID: 20684669
[TBL] [Abstract][Full Text] [Related]
8. 5% lidocaine-medicated plaster vs other relevant interventions and placebo for post-herpetic neuralgia (PHN): a systematic review.
Wolff RF; Bala MM; Westwood M; Kessels AG; Kleijnen J
Acta Neurol Scand; 2011 May; 123(5):295-309. PubMed ID: 21039364
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility of pregabalin as add-on to usual care versus usual care alone in the management of peripheral neuropathic pain in Belgium.
Chevalier P; Lamotte M; Van Campenhout H; Eyckerman R; Annemans L
J Med Econ; 2013; 16(5):596-605. PubMed ID: 23409950
[TBL] [Abstract][Full Text] [Related]
10. A retrospective evaluation of the use of gabapentin and pregabalin in patients with postherpetic neuralgia in usual-care settings.
Gore M; Sadosky A; Tai KS; Stacey B
Clin Ther; 2007 Aug; 29(8):1655-70. PubMed ID: 17919547
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of pregabalin in the treatment of fibromyalgia from a UK perspective.
Choy E; Richards S; Bowrin K; Watson P; Lloyd A; Sadosky A; Zlateva G
Curr Med Res Opin; 2010 Apr; 26(4):965-75. PubMed ID: 20178405
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of 5% lidocaine (lignocaine) medicated plaster in comparison with pregabalin in patients with postherpetic neuralgia and diabetic polyneuropathy: interim analysis from an open-label, two-stage adaptive, randomized, controlled trial.
Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
Clin Drug Investig; 2009; 29(4):231-41. PubMed ID: 19301937
[TBL] [Abstract][Full Text] [Related]
13. 5% lidocaine medicated plaster in elderly patients with postherpetic neuralgia: results of a compassionate use programme in France.
Clère F; Delorme-Morin C; George B; Navez M; Rioult B; Tiberghien-Chatelain F; Ganry H
Drugs Aging; 2011 Sep; 28(9):693-702. PubMed ID: 21913735
[TBL] [Abstract][Full Text] [Related]
14. Review of current guidelines on the care of postherpetic neuralgia.
Argoff CE
Postgrad Med; 2011 Sep; 123(5):134-42. PubMed ID: 21904096
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of pregabalin versus gabapentin in the management of neuropathic pain due to diabetic polyneuropathy or post-herpetic neuralgia.
Rodríguez MJ; Díaz S; Vera-Llonch M; Dukes E; Rejas J
Curr Med Res Opin; 2007 Oct; 23(10):2585-96. PubMed ID: 17875242
[TBL] [Abstract][Full Text] [Related]
16. Pregabalin and gabapentin in matched patients with peripheral neuropathic pain in routine medical practice in a primary care setting: Findings from a cost-consequences analysis in a nested case-control study.
Pérez C; Navarro A; Saldaña MT; Masramón X; Rejas J
Clin Ther; 2010 Jul; 32(7):1357-70. PubMed ID: 20678683
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of 5% lidocaine-medicated plaster compared with pregabalin for the treatment of post-herpetic neuralgia in China.
Zeng F; Wang M; Zhang D
Ann Palliat Med; 2021 Apr; 10(4):4493-4501. PubMed ID: 33894728
[TBL] [Abstract][Full Text] [Related]
18. 5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.
Baron R; Mayoral V; Leijon G; Binder A; Steigerwald I; Serpell M
Curr Med Res Opin; 2009 Jul; 25(7):1663-76. PubMed ID: 19485723
[TBL] [Abstract][Full Text] [Related]
19. Long-term treatment of neuropathic pain with a 5% lidocaine medicated plaster.
Wilhelm IR; Tzabazis A; Likar R; Sittl R; Griessinger N
Eur J Anaesthesiol; 2010 Feb; 27(2):169-73. PubMed ID: 20010108
[TBL] [Abstract][Full Text] [Related]
20. Long-term cost-effectiveness of initiating treatment for painful diabetic neuropathy with pregabalin, duloxetine, gabapentin, or desipramine.
Bellows BK; Nelson RE; Oderda GM; LaFleur J
Pain; 2016 Jan; 157(1):203-213. PubMed ID: 26397932
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
